Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose - Dataset

Published: 23 June 2021| Version 1 | DOI: 10.17632/5bjwph8xkr.1
Andres Rossi, Diego S Ojeda, Augusto Varese, Lautaro N Sanchez, Maria Mora Gonzalez Lopez Ledesma, Santiago Oviedo Rouco, Horacio M Pallares, Guadalupe Costa Navarro, Andrea Gamarnik


Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluated SARS CoV-2-specific antibody responses after Sputnik V vaccination of 206,000 healthcare workers in Buenos Aires, Argentina, measuring IgG anti-spike antibody titers and virus neutralizing capacity after one and two doses in a cohort of naïve or previously infected volunteers (N=288). By 21 days after receiving the first dose of vaccine, 94% of naïve participants had developed spike-specific IgG antibodies (96% and 89% of participants <60 and >60 years old, respectively), whereas 100% of participants had acquired spike-specific antibodies by 21 days after receiving a second vaccine dose. A single Sputnik V dose elicited higher spike-specific antibody levels and virus neutralizing capacity in previously infected individuals than in individuals without prior infection receiving the full two-dose schedule. The high seroconversion rate after a single vaccine dose in naïve participants suggests evaluating the benefit of delaying second dose administration to increase the number of people vaccinated. The data presented provide new information for guiding public health decisions in light of the current global health emergency.



Vaccine, Antibody, Neutralizing Antibody, Argentina, COVID-19